Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma

Abstract

Bispecific antibodies play an important role in immunotherapy. They have received intense interest from pharmaceutical enterprises. The first antibody drug, OKT3 (muromonab-CD3), showed great performance in clinical treatment. We have successfully developed a single-chain variable fragment (ScFv) combination of anti-CD3 ScFv and anti-CD138 ScFv with the hIgG1 Fc (hIgFc) sequence. The novel bispecific T-cell engager (BiTE) with an additional hIgFc (BiTE-hIgFc, STL001) can target T cells, natural killer cells, and multiple myeloma cells (RPMI-8226 or U266). In addition, BiTE-hIgFc (STL001) has nanomolar-level affinity to recombinant human CD138 protein and shows more potent antitumor activity against RPMI-8226 cells than that of separate aCD3-ScFv-hIgFc and aCD138-ScFv-hIgFc, or the isotype mAb in vitro or in vivo.

DOI: 10.1111/cas.12631

Extracted Key Phrases

5 Figures and Tables

010020030020162017
Citations per Year

116 Citations

Semantic Scholar estimates that this publication has 116 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@inproceedings{Zou2015ImmunotherapyBO, title={Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma}, author={Jianxuan Zou and Dan Chen and Yunhui Zong and Sisi Ye and J. -C. Tang and Huimin Meng and Gangli An and Xingding Zhang and Lin Yang}, booktitle={Cancer science}, year={2015} }